Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07126678 | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma | recruiting | N/A | 15 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT04892667 | Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG(DETECT) | active not recruiting | N/A | 128 | Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Aug 13, 2025 |
| clinicaltrials |
| NCT07088783 | Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients(OCARE-MM) | active not recruiting | N/A | 60 | OzlemOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07074470 | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL(VPX) | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07072208 | Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL | recruiting | N/A | 43 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072221 | Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07070960 | A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible(CAR-T) | not yet recruiting | N/A | 35 | Xuzhou Medical UniversityOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT07059741 | Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL | recruiting | N/A | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06689917 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Tongji HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07034755 | Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma | not yet recruiting | N/A | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06871176 | PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | recruiting | N/A | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06785324 | Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)(NEOMA ALL) | recruiting | N/A | 20 | University of ChicagoOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07018271 | A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients | not yet recruiting | N/A | 24 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Jun 12, 2025 | clinicaltrials |
| NCT07015021 | The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients(DKPD) | not yet recruiting | N/A | 72 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Jun 11, 2025 | clinicaltrials |
| NCT06940960 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05036564 | Diagnosis; Objective RespOnse; THErApy(DOROTHEA) | recruiting | N/A | 70 | IRCCS San RaffaeleOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04898647 | Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia(SLPRaresHvisc) | recruiting | N/A | 100 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06890065 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06942507 | Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia(BRZ-WM) | not yet recruiting | N/A | 104 | Peking Union Medical College HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06946407 | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | recruiting | N/A | 41 | FengYan JinOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06699394 | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis | recruiting | N/A | 20 | Peking University People's HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05956457 | PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma | recruiting | N/A | 100 | Pack HealthINDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06925958 | A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma | not yet recruiting | N/A | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT02964858 | Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.(DOBL) | recruiting | N/A | 840 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06924424 | Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | active not recruiting | N/A | 105 | Peking University People's HospitalOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT05945524 | Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination(ResisTec) | recruiting | N/A | 100 | University Hospital, ToulouseOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05259553 | Biomarkers in Multiple Myeloma(VESICOM) | recruiting | N/A | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06902025 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia | not yet recruiting | N/A | 24 | He HuangOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06888752 | LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 35 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06883604 | Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin(PRO-Hodgkin) | recruiting | N/A | 75 | Uppsala University HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06581081 | Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia | recruiting | N/A | 130 | Peking University People's HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06832267 | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | recruiting | N/A | 44 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06817759 | Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer | not yet recruiting | N/A | 60 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06813573 | Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma(EVOLITION) | recruiting | N/A | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06783816 | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors | recruiting | N/A | 45 | Shanxi Bethune HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06781515 | Assessment of Disease Burden in Hairy Cell Leukemia(BRAF) | recruiting | N/A | 45 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06761274 | Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma(MEPI-AGE) | recruiting | N/A | 200 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06741813 | Allo-HSCT vs ASCT in Adult T-LBL(TROPHY-NHL01) | not yet recruiting | N/A | 230 | Peking University People's HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT05053607 | Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab | recruiting | N/A | 50 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06608147 | MOLyF : Bone Marrow and Follicular Lymphoma(MOLyF) | recruiting | N/A | 200 | Rennes University HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04726787 | RadiothErapy priMIng for CAR-T(REMIT) | active not recruiting | N/A | 6 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04533217 | Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. | recruiting | N/A | 90 | Spine Centre of Southern DenmarkOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | recruiting | N/A | 100 | Peking University People's HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05333367 | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy(MORPHEE) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06678282 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06671717 | Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | not yet recruiting | N/A | 25 | Peking University People's HospitalOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05662540 | PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06658938 | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2025source: clinicaltrials